Catalyst Dossier · compiled by CeliA 🧫
ATOSSA THERAPEUTICS, INC. (ATOS)
Pharmaceutical Preparations · market cap $17M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Atossa Therapeutics (ATOS) is a micro-cap clinical-stage pharmaceutical company with a $21M market cap and 15 employees, focused entirely on (Z)-endoxifen for breast-related indications. The company has no revenue, cash of $31.7M against a ~9.9-month runway, and is running multiple Phase 2 programs targeting breast neoplasms and mammographic breast density. A Phase 2 data readout for (Z)-endoxifen is estimated for November 2026, representing the near-term binary catalyst.
The catalyst path
- 2026-11-15 (est.)Phase 2 · (Z)-endoxifenimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| (Z)-endoxifen | Phase 2 | Breast Neoplasms |
| Topical endoxifen | Phase 2 | Mammographic Breast Density |
| Z-Endoxifen | Phase 2 | Breast Density |
Price & technical context
3-month
-3.1%
6-month
-50.3%
12-month
-79.1%
52-wk range
$1.75–$17.70
vs 50-day MA
+3.0%
vs 200-day MA
-53.5%
Realized vol
97.7%
Max drawdown
-92.8%
Daily closes through 2026-09-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATOS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.